Shineco, Inc. (SISI)
USD 2.12
(-4.07%)
USD 2.12
(-4.07%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 17.94 Million USD | 102.03% |
| 2023 | 8.88 Million USD | -56.15% |
| 2022 | 20.25 Million USD | 17.95% |
| 2021 | 17.17 Million USD | 78.75% |
| 2020 | 9.6 Million USD | 8.51% |
| 2019 | 8.85 Million USD | 60.57% |
| 2018 | 5.51 Million USD | 67.43% |
| 2017 | 3.29 Million USD | -12.0% |
| 2016 | 3.74 Million USD | -2.65% |
| 2015 | 3.84 Million USD | 54.73% |
| 2014 | 2.48 Million USD | 4.12% |
| 2013 | 2.38 Million USD | 0.0% |
| 2006 | 827.23 Thousand USD | 127.55% |
| 2005 | 363.53 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 2.07 Million USD | -63.62% |
| 2024 Q1 | 3.33 Million USD | 53.38% |
| 2024 Q2 | 5.69 Million USD | 71.07% |
| 2024 Q4 | 5.5 Million USD | 165.6% |
| 2023 Q1 | 1.81 Million USD | -75.84% |
| 2023 Q2 | 2.32 Million USD | 28.2% |
| 2023 Q4 | 2.17 Million USD | -12.77% |
| 2023 Q3 | 2.48 Million USD | 7.18% |
| 2023 FY | 8.88 Million USD | -56.15% |
| 2022 Q2 | 1.94 Million USD | -77.36% |
| 2022 FY | 20.25 Million USD | 17.95% |
| 2022 Q1 | 8.58 Million USD | 147.69% |
| 2022 Q4 | 7.5 Million USD | 235.69% |
| 2022 Q3 | 2.23 Million USD | 15.01% |
| 2021 Q2 | 6.8 Million USD | 267.14% |
| 2021 Q1 | 1.85 Million USD | 2582.68% |
| 2021 Q3 | 5.04 Million USD | -25.83% |
| 2021 Q4 | 3.46 Million USD | -31.38% |
| 2021 FY | 17.17 Million USD | 78.75% |
| 2020 Q1 | 3.47 Million USD | 125.22% |
| 2020 Q2 | 2.16 Million USD | -37.71% |
| 2020 Q3 | 4.04 Million USD | 86.65% |
| 2020 Q4 | -74.69 Thousand USD | -101.85% |
| 2020 FY | 9.6 Million USD | 8.51% |
| 2019 Q4 | 1.54 Million USD | -58.68% |
| 2019 Q3 | 3.73 Million USD | 101.63% |
| 2019 FY | 8.85 Million USD | 60.57% |
| 2019 Q1 | 1.72 Million USD | 17.94% |
| 2019 Q2 | 1.85 Million USD | 7.43% |
| 2018 Q4 | 1.46 Million USD | 8.77% |
| 2018 FY | 5.51 Million USD | 67.43% |
| 2018 Q3 | 1.34 Million USD | -14.85% |
| 2018 Q2 | 1.57 Million USD | 39.64% |
| 2018 Q1 | 1.13 Million USD | 1354.19% |
| 2017 Q4 | 77.74 Thousand USD | -91.69% |
| 2017 Q1 | 854.08 Thousand USD | 1.83% |
| 2017 Q2 | 1.42 Million USD | 67.03% |
| 2017 Q3 | 935.82 Thousand USD | -34.4% |
| 2017 FY | 3.29 Million USD | -12.0% |
| 2016 Q3 | 824.47 Thousand USD | -11.66% |
| 2016 Q1 | 1 Million USD | -23.71% |
| 2016 Q4 | 838.69 Thousand USD | 1.73% |
| 2016 FY | 3.74 Million USD | -2.65% |
| 2016 Q2 | 933.33 Thousand USD | -6.95% |
| 2015 FY | 3.84 Million USD | 54.73% |
| 2015 Q4 | 1.31 Million USD | 77.84% |
| 2015 Q3 | 739.27 Thousand USD | -12.97% |
| 2015 Q2 | 849.48 Thousand USD | -9.78% |
| 2015 Q1 | 941.56 Thousand USD | 308.53% |
| 2014 Q4 | 230.47 Thousand USD | -78.1% |
| 2014 Q2 | 420.64 Thousand USD | 0.0% |
| 2014 Q3 | 1.05 Million USD | 150.2% |
| 2014 Q1 | 420.64 Thousand USD | -34.98% |
| 2014 FY | 2.48 Million USD | 4.12% |
| 2013 Q4 | 646.94 Thousand USD | 28.4% |
| 2013 FY | 2.38 Million USD | 0.0% |
| 2013 Q3 | 503.84 Thousand USD | 0.0% |
| 2007 Q3 | 215.99 Thousand USD | 0.0% |
| 2007 Q1 | 242.64 Thousand USD | 0.0% |
| 2006 Q3 | 195.4 Thousand USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 FY | 827.23 Thousand USD | 127.55% |
| 2005 FY | 363.53 Thousand USD | 0.0% |
| 2005 Q3 | 323.74 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Theratechnologies Inc. | 72.75 Million USD | 75.331% |
| Harrow Health, Inc. | 89.97 Million USD | 80.052% |
| Dynavax Technologies Corporation | 219.14 Million USD | 91.81% |
| Biofrontera Inc. | 39.95 Million USD | 55.084% |
| Cronos Group Inc. | 96.7 Million USD | 81.441% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -90.007% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 92.268% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | 54.159% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 287.721% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | 58.3% |
| Radius Health, Inc. | 265.92 Million USD | 93.251% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -29.664% |
| DURECT Corporation | 43.71 Million USD | 58.943% |
| ProPhase Labs, Inc. | 37.85 Million USD | 52.584% |
| Safety Shot Inc | 12.1 Million USD | -48.212% |
| Phibro Animal Health Corporation | 260.29 Million USD | 93.105% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -484.781% |
| Alvotech | 285.43 Million USD | 93.712% |
| Assertio Holdings, Inc. | 368.58 Million USD | 95.131% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 96.607% |
| Rockwell Medical, Inc. | 15.37 Million USD | -16.743% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -36.752% |
| Procaps Group S.A. | 187.24 Million USD | 90.415% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 96.958% |
| SCYNEXIS, Inc. | 51.84 Million USD | 65.383% |
| Aytu BioPharma, Inc. | 59.84 Million USD | 70.007% |
| Viatris Inc. | 5.96 Billion USD | 99.699% |
| OptiNose, Inc. | 85.1 Million USD | 78.91% |
| SIGA Technologies, Inc. | 22.04 Million USD | 18.577% |
| Tilray Brands, Inc. | 251.35 Million USD | 92.86% |
| PetIQ, Inc. | 192.72 Million USD | 90.687% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -36.752% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 98.876% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -84.445% |
| Alimera Sciences, Inc. | 62.64 Million USD | 71.348% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | 88.727% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -2253.866% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -204.95% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 94.287% |
| Journey Medical Corporation | 54.59 Million USD | 67.125% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -0.783% |
| Alpha Teknova, Inc. | 45.85 Million USD | 60.863% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | 15.215% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | 63.4% |
| PainReform Ltd. | 9.58 Million USD | -87.271% |
| Cosmos Health Inc. | 26.18 Million USD | 31.446% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 89.12% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -82.677% |
| Embecta Corp. | 528.4 Million USD | 96.603% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -349.697% |
| Talphera, Inc. | 11.99 Million USD | -49.642% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 94.501% |
| Incannex Healthcare Limited | 30.05 Million USD | 40.279% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | 14.704% |
| Procaps Group, S.A. | 199.47 Million USD | 91.002% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 90.842% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | 59.986% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 94.796% |
| Alvotech | 285.43 Million USD | 93.712% |
| Hempacco Co., Inc. | 7.59 Million USD | -136.269% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | 87.245% |
| Bright Green Corporation | 8.25 Million USD | -117.476% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 93.399% |
| Kamada Ltd. | 45.42 Million USD | 60.49% |
| Indivior PLC | 911 Million USD | 98.03% |
| Evoke Pharma, Inc. | 12.4 Million USD | -44.63% |
| Flora Growth Corp. | 10.57 Million USD | -69.657% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | 14.704% |
| Evolus, Inc. | 189.75 Million USD | 90.542% |
| HUTCHMED (China) Limited | 436.23 Million USD | 95.886% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 88.356% |
| Akanda Corp. | 3.48 Million USD | -415.229% |